By November 27, 2024, under the U.S.Drug Supply Chain Security Act (DSCSA) the pharmaceutical supply chain must exchange product compliance information, including drug verification and tracing data, in a fully interoperable manner. To ensure seamless authentication and prevent bad actors from accessing sensitive information, LedgerDomain and rfxcel provide a joint approach for trading partners based on specifications developed in close collaboration with industry stakeholders, including the Partnership for DSCSA Governance (PDG) the Healthcare Distribution Alliance (HDA) VRS Working Group, GS1 US, and the Open Credentialing Initiative (OCI).
In this webinar, LedgerDomain, rfxcel, and fellow OCI member Spherity gather to discuss the Authorized Trading Partner (ATP) validation requirements of the DSCSA.
